Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients

Purpose The aim of this study was to evaluate clinical outcomes of second-line chemotherapy with capecitabine and cyclophosphamide (CTX) plus thalidomide and prednisone in refractory advanced castrate-resistant prostate cancer (CRPC) patients. Methods We retrospectively reviewed patients with advanc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2012-02, Vol.138 (2), p.333-339
Hauptverfasser:	Meng, Li-Juan, Wang, Jun, Fan, Wei-Fei, Pu, Xiao-Lin, Liu, Fu-Yin, Yang, Min
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Research Capecitabine Chemotherapy Clinical outcomes Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease-Free Survival Drug delivery systems Drug Resistance, Neoplasm Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Follow-Up Studies Gynecology. Andrology. Obstetrics Hematology Humans Internal Medicine Male Male genital diseases Medical sciences Medicine Medicine & Public Health Nephrology. Urinary tract diseases Oncology Original Paper Pharmacology. Drug treatments Prednisone - administration & dosage Prednisone - adverse effects Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Retrospective Studies Thalidomide - administration & dosage Thalidomide - adverse effects Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!